High-risk Human Papillomavirus (hrHPV) Prevalence and Genotype Distribution Among Turkish Women

Overview

Journal J Cytol

Specialty Cell Biology

Date 2023 May 14

PMID 37179966

Authors

Melin Gecer

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to determine the rates of distribution of high-risk HPV (hrHPV) genotypes according to cervical smear samples and biopsy results in a large sample of Turkish women.

Methods: The study was conducted with 4,503 healthy volunteer women aged 19-65 years. Samples of cervical smears were collected during the examination and liquid-based cytology was used for the Pap tests. The Bethesda system was used for reporting the cytology. High-risk HPV genotypes including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were investigated in samples. The study cohort was grouped according to age in decades, with comparisons made according to these age groups, Bethesda class, and cervix biopsy results.

Results: Among all cases, 903 (20.1%) participants were positive for 1074 hrHPV-DNA genotypes. HPV-DNA positive cases were most common in the 30-39 age group (28.0%), followed by women under the age of 30 (38.5%). HPV genotypes were determined as, in order of frequency: Other hrHPV (n = 590, 65.3%), HPV16 (n = 127, 14.1%), Other HPV + HPV16 (n = 109, 12.1%), HPV 18 (n = 33, 3.6%), and Other HPV + HPV 18 (n = 32, 3.5%). Cervical smears were reported as ASCUS in 304 (6.8%) samples and high-grade squamous intraepithelial lesion (HSIL) in 12 (0.3%) of the samples. Biopsy demonstrated the presence of HSIL in 110 (12.5%) participants, with 644 (73.3%) negative cases.

Conclusion: This showed an increasing incidence of Other HPVs besides the known importance of HPV 16 and 18 genotypes as risk factors for cervical cancer.

Citing Articles

Cellular Retinoic Acid Binding Protein 2 (CRABP2), Up-regulated by HPV E6/E7, Leads to Aberrant Activation of the Integrin β1/FAK/ERK Signaling Pathway and Aggravates the Malignant Phenotypes of Cervical Cancer.

Liu J, Tang L, Chu W, Wei L Biochem Genet. 2023; 62(4):2686-2701.

PMID: 38001389 DOI: 10.1007/s10528-023-10568-6.

References

Demirci M, Guzel A, Ersahin A, Yorulmaz E, Suphan Ersahin S, Borsa B . Human papillomavirus prevalence and genotype distribution among Turkish women with or without cervical lesion. Indian J Med Microbiol. 2019; 36(4):517-521. DOI: 10.4103/ijmm.IJMM_18_232. View

Chan K, Liu S, Wei N, Ngu S, Chu M, Tse K . Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population. Int J Cancer. 2020; 147(4):1152-1162. DOI: 10.1002/ijc.32861. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N . European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol. 2010; 21(3):448-458. PMC: 2826099. DOI: 10.1093/annonc/mdp471. View

Bakir A, Alacam S, Karabulut N, Beka H, Ozluk Y, Yilmazbayhan D . Evaluation of Human Papillomavirus Genotype Distribution in Cervical Samples. J Cytol. 2021; 38(1):44-49. PMC: 8078615. DOI: 10.4103/JOC.JOC_19_19. View

Usubutun A, Alemany L, Kucukali T, Ayhan A, Yuce K, de Sanjose S . Human papillomavirus types in invasive cervical cancer specimens from Turkey. Int J Gynecol Pathol. 2009; 28(6):541-8. DOI: 10.1097/PGP.0b013e3181aaba0d. View

Gultekin M, Karaca M, Kucukyildiz I, Dundar S, Boztas G, Semra Turan H . Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2017; 142(9):1952-1958. PMC: 5888190. DOI: 10.1002/ijc.31212. View

Clifford G, Tully S, Franceschi S . Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer. Clin Infect Dis. 2017; 64(9):1228-1235. PMC: 5399941. DOI: 10.1093/cid/cix135. View

Dursun P, Senger S, Arslan H, Kuscu E, Ayhan A . Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit. BMC Infect Dis. 2009; 9:191. PMC: 2789077. DOI: 10.1186/1471-2334-9-191. View

10.

Dursun P, Ayhan A, Mutlu L, Caglar M, Haberal A, Gungor T . HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers. Turk Patoloji Derg. 2013; 29(3):210-6. DOI: 10.5146/tjpath.2013.01188. View

11.

Kulhan M, Kulhan N, Seven Y, Nayki U, Nayki C, Ata N . Estimation of the prevalence and distribution of HPV genotypes and identification of related risk factors among Turkish women. Contemp Oncol (Pozn). 2017; 21(3):218-223. PMC: 5701576. DOI: 10.5114/wo.2017.69591. View

12.

Yuce K, Pinar A, Salman M, Alp A, Sayal B, Dogan S . Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study. Arch Gynecol Obstet. 2012; 286(1):203-8. DOI: 10.1007/s00404-012-2280-z. View

13.

Nayar R, Wilbur D . The Pap test and Bethesda 2014. Cancer Cytopathol. 2015; 123(5):271-81. DOI: 10.1002/cncy.21521. View

14.

Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A . Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; . DOI: 10.1002/ijc.33588. View

15.

Gultekin M, Dundar S, Keskinkilic B, Turkyilmaz M, Ozgul N, Yuce K . How to triage HPV positive cases: Results of four million females. Gynecol Oncol. 2020; 158(1):105-111. DOI: 10.1016/j.ygyno.2020.04.698. View

16.

Ghosh T, VandeHaar M, Rivera M, Henry M . High-risk HPV genotype distribution in HPV co-test specimens: study of a predominantly Midwestern population. J Am Soc Cytopathol. 2019; 7(2):99-105. DOI: 10.1016/j.jasc.2017.09.007. View

17.

Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P . The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2020; 148(2):277-284. PMC: 7754400. DOI: 10.1002/ijc.33189. View

18.

Darragh T, Colgan T, Cox J, Heller D, Henry M, Luff R . The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2012; 32(1):76-115. DOI: 10.1097/PGP.0b013e31826916c7. View

19.

Demir E, Ceyhan M, Simsek M, Gunduz T, Arlier S, Aytac R . The prevalence of different HPV types in Turkish women with a normal Pap smear. J Med Virol. 2012; 84(8):1242-7. DOI: 10.1002/jmv.23333. View

20.

Curry S, Krist A, Owens D, Barry M, Caughey A, Davidson K . Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 320(7):674-686. DOI: 10.1001/jama.2018.10897. View